FDA approval: Ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer

Clinical Cancer Research

Volumn 20, Issue 17, 2014, Pages 4436-4441

  Amiri Kordestani, Laleh ^a   Blumenthal, Gideon M ^a   Xu, Qiang Casey ^a   Zhang, Lijun ^a   Tang, Shenghui W ^a   Ha, Linan ^a   Weinberg, Wendy C ^a   Chi, Bo ^a   Candau Chacon, Reyes ^a   Hughes, Patricia ^a   Russell, Anne M ^a   Miksinski, Sarah Pope ^a   Chen, Xiao Hong ^a   McGuinn, W David ^a   Palmby, Todd ^a   Schrieber, Sarah J ^a   Liu, Qi ^a   Wang, Jian ^a   Song, Pengfei ^a   Mehrotra, Nitin ^a   Skarupa, Lisa ^a   Clouse, Kathleen ^a   Al Hakim, Ali ^a   Sridhara, Rajeshwari ^a   Ibrahim, Amna ^a   Justice, Robert ^a   Pazdur, Richard ^a   Cortazar, Patricia ^a   more..

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; LAPATINIB; TRASTUZUMAB EMTANSINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MAYTANSINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; CANCER SURVIVAL; CONSTIPATION; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART LEFT VENTRICLE FAILURE; HEPATOBILIARY DISEASE; HUMAN; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; XEROSTOMIA; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETICS; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG APPROVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MAYTANSINE; MIDDLE AGED; RECEPTOR, ERBB-2; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84936074960     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0012     Document Type: Review

References (25)

1. Yarden Y, Sliwkowski MX. Untangling the cErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
3. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010;28:92-8.
4. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009;14:320-68.
5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
6. Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013;14:461-71.
7. Department of Health and Human Services. Approval letter [cited 2014 May 7]; p.13. Silver Spring (MD): U.S. Food and Drug Administration; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2013/125427Orig1s000Approv.pdf
8. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006;66:4426-33.
9. Erickson HK, Lewis Phillips GD, Leipold DD, Provenzano C, Mai E, Johnson HA, et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther 2012;11:1133-42.
10. Oroudjev E, Lopus M, Wilson L, Audette C, Provenzano C, Erickson H, et al. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther 2010;9:2700-13.
11. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-drug conjugate. Cancer Res 2008;68:9280-90.
12. Junttila TT, Li G, Parsons K, Lewis Phillips G, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib-insensitive breast cancer. Breast Cancer Res Treat 2011;128:347-56.
13. U.S. Food and Drug Administration. Clinical pharmacology and biopharmaceutics review(s). [cited 2014 May 7]; p. 13. Silver Spring (MD): U.S. Food and Drug Administration; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2013/125427Orig1-s000ClinPharmR.pdf.
14. Verma S, Miles D, Gianni L, Kropp IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91.
15. Burris HA III, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29:398-405.
16. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012;30:3234-41.
17. Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2013;31:1157-63.
18. Blum RH, Kahlert T. Maytansine: a phase I study of an ansa macrolide with antitumor activity. Cancer Treat Rep 1978;62:435-8.
19. Eagan RT, Ingle JN, Rubin J, Frytak S, Moertel CG. Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communication. J Natl Cancer Inst 1978;60:93-6.
20. Cabanillas F, Rodriguez V, Hall SW, Burgess MA, Bodey GP, Freireich EJ. Phase I study of maytansine using a 3-day schedule. Cancer Treat Rep 1978;62:425-8.
21. Labeling [cited 2014May 7]; p. 21. Reference ID: 3265306. Silver Spring (MD): U.S. Food and Drug Administration; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125427lbl.pdf.
22. Montemurro F, Di Cosimo S, Arpino G. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Ann Oncol 2013;24:2715-24.
23. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-75.
24. Tsang RY, Finn RS. Beyond trastuzumab; novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer 2012;106: 6-13.
25. Stern HM. Improving treatment of HER2-positive cancers: opportunities and challenges. Sci Transl Med 2012;4:127rv2.